# Solara Active Pharma Sciences (NSE: SOLARA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SOLARA · Pivot · prices to 22 Oct 2026

Solara Active Pharma Sciences (NSE: SOLARA) closed at ₹650.75 on 22 Oct 2026, up 1.48% on the day. With a market capitalisation of ₹3,140 Cr, it ranks 953rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −0.6% in FY26. Over the past year the share price has risen 11.8%. Its 52-week range is ₹422.00 (30 Mar 2026) to ₹774.00 (15 Sep 2026); the last close is 15.9% below the high. Promoters held 41.93% of the company as of 30 Jun 2026; 37.11% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹650.75 |
| Market cap | ₹3,140 Cr |
| ROE | −0.6% (FY26) |
| ROCE | 6.5% (FY26) |
| Debt to equity | 0.53 |
| 52-week high | ₹774.00 (15 Sep 2026) |
| 52-week low | ₹422.00 (30 Mar 2026) |
| 1-year return | +11.8% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,284 Cr | ₹1 Cr |
| FY24 | ₹1,289 Cr | −₹567 Cr |
| FY23 | ₹1,444 Cr | −₹22 Cr |
| FY22 | ₹1,268 Cr | −₹58 Cr |
| FY21 | ₹1,617 Cr | ₹221 Cr |
| FY20 | ₹1,322 Cr | ₹115 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 41.93%
- Foreign institutions: 11.52%
- Domestic institutions: 3.74%
- Non-institutions: 42.81%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | ₹495.95 | ₹3,492 Cr | 13.8 | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | ₹381.15 | ₹3,479 Cr | 17.9 | — |
| [Ind-Swift Laboratories](https://app.pivotnow.in/stock/INDSWFTLAB) | ₹347.05 | ₹3,018 Cr | 71.6 | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |
| [Shukra Pharma](https://app.pivotnow.in/stock/SHUKRAPHAR) | ₹63.62 | ₹2,797 Cr | 127.2 | — |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |

## Questions and answers

### What is the share price of Solara Active Pharma Sciences today?

Solara Active Pharma Sciences (NSE: SOLARA) last closed at ₹650.75 on 22 Oct 2026. Its 52-week high is ₹774.00 and its 52-week low is ₹422.00.

### What is the market cap of Solara Active Pharma Sciences?

Solara Active Pharma Sciences' market capitalisation is ₹3,140 Cr (₹3,140 Cr) at the 22 Oct 2026 close, ranking 953rd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Solara Active Pharma Sciences?

Return on equity was −0.6% in FY26 and return on capital employed was 6.5% in FY26 (consolidated figures).

### Is Solara Active Pharma Sciences a debt-free company?

No. Solara Active Pharma Sciences' debt-to-equity ratio was 0.53 in FY26, with total debt of ₹110 Cr.

### How has Solara Active Pharma Sciences stock performed over the last year?

Solara Active Pharma Sciences' share price has risen 11.8% over the past year, +21.2% over three months and −13.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Solara Active Pharma Sciences?

As of 30 Jun 2026: promoters 41.93%, foreign institutions 11.52%, domestic institutions 3.74%, non-institutions 42.81%. 37.11% of promoter shares were pledged.

### Who are Solara Active Pharma Sciences' competitors?

The listed Pharma & Healthcare companies closest to Solara Active Pharma Sciences by market cap are Unichem Laboratories, Aarti Drugs, Ind-Swift Laboratories, Advanced Enzyme Technologies, Shukra Pharma and Dishman Pharma.

### Is Solara Active Pharma Sciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Solara Active Pharma Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SOLARA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.